NIH Clinical Research Studies

Protocol Number: 08-EI-0103

Active Accrual, Protocols Recruiting New Patients

Title:
High Speed Indocyanine Green Angiography Findings in Induction / PRN Regimen of Intravitreal Ranibizumab Injection for Neovascular Age-Related Macular Degeneration
Number:
08-EI-0103
Summary:
This study will use an eye imaging test called high speed indocyanine green angiography (HS-ICG), which examines leaky vessels in the eye, to try to find out why individuals respond differently to ranibizumab (Lucentis) treatment for wet age-related macular degeneration (AMD). The drug was recently approved by the Food and Drug Administration to treat this disease, but the response to the treatment varies markedly among individuals.

People 50 years of age and older with wet AMD and vision that meets the research protocol criteria may be eligible for this study. Participants undergo the following procedures:

Ranibizumab injections in the study eye once a month for 4 months. Additional injections are given only if the study eye shows signs of bleeding or leaking fluid. The eye is numbed before the injection and the eye area is cleaned with an antiseptic. Antibiotic drops are used for 3 days following the injection to prevent infection.

Clinic visits once a month for 2 years for evaluations to monitor the response to treatment. The evaluations may include the following examinations and tests:

-Eye examination with dilation, optical coherence tomography and photography: The examination measures visual acuity, thickness of your retina (the back of the eye) andeye pressure. Bright lights will also be used so that the doctor can see the back of your eye. Photographs of the eye may be taken.

-Fluorescein angiography to examine the blood vessels in the eye: A dye called fluorescein is injected into a vein in the arm. The dye travels through the veins to the blood vessels in the eyes. A camera takes pictures of the dye as it flows through the blood vessels. This test is done eight times during the study.

-Indocyanine green angiography to examine the blood vessels in the eye: The procedure is the same as for fluorescein angiography, but it uses a dye called indocyanine green. This test is done once a month for the first year of the study and then every 3 months.

Sponsoring Institute:
National Eye Institute (NEI)
Recruitment Detail
Type: Participants currently recruited/enrolled
Gender: Male & Female
Referral Letter Required: No
Population Exclusion(s): Children

Eligibility Criteria:
INCLUSION CRITERIA

-The participant must understand and sign the IRB-approved informed consent document for the study.

-The participant must be 50 years old or older.

-The participant must be diagnosed with AMD in at least one eye as defined by the presence of drusen at least 63 micrometer in size.

-The participant must have CNV secondary to AMD as determined by the investigator.

-The participant must have visual acuity of better than 20/400 in the affected eye as measured on an ETDRS chart.

-The participant has retinal photographs and angiography of sufficient quality, allowing assessment of the macular area according to standard clinical practice.

-Women participants of childbearing potential must not be pregnant or breast-feeding, must have a negative pregnancy test at screening and must practice an adequate method of birth control. Acceptable methods of birth control include intrauterine device (IUD); oral, dermal ( patch ), implanted or injected contraceptives; hormonal contraception; tubal ligation; and barrier methods with spermicide. If a participant is of child-bearing potential, she must be willing to undergo a urine pregnancy test every 4-5 weeks.

-The participant must be willing and able to comply with the protocol.

EXCLUSION CRITERIA

-The participant has CNV associated with other ocular diseases such as pathologic myopia, ocular histoplasmosis or posterior uveitis, etc.

-The participant has geographic atrophy or fibrosis under the fovea.

-The participant has decreased vision due to retinal disease not attributable to CNV, such as nonexudative forms of AMD, geographic atrophy, inherited retinal dystrophy, uveitis, or epiretinal membrane.

-The participant has any additional ocular diseases that have irreversibly compromised or could likely compromise the visual acuity of the study eye including amblyopia, anterior ischemic optic neuropathy, clinically significant diabetic macular edema, severe non proliferative diabetic retinopathy, or proliferative diabetic retinopathy.

-The participant has decreased vision due to significant media opacity such as corneal disease or cataract, or opacity precluding photography of the retina; a tear of the RPE; a vitelliform-like lesion of the outer retina (e.g., as in pattern dystrophies or basal laminar cuticular drusen), idiopathic parafoveal telangiectasis, or central serous chorioretinopathy.

-The participant has a history of treatment for CNV in the study eye with focal laser photocoagulation (subfoveal, juxtafoveal or extrafoveal), verteporfin/photodynamic therapy, transpupillary thermotherapy, external beam radiation therapy, or other local treatment (such as submacular surgery).

-The participant has had previous ranibizumab, bevacizumab or pegaptanib sodium treatments in the study or fellow eye less than four weeks prior to enrollment.

-The participant has had prior verteporfin/photodynamic therapy in the fellow eye less than one week prior to enrollment.

-The participant has had prior intravitreal or peribulbar corticosteroids in the study or fellow eye less than 12 weeks prior to enrollment.

-The participant has evidence of ocular toxoplasmosis; external ocular infection, including conjunctivitis; chalazion; significant blepharitis; or aphakia in the study eye.

-The participant has a history of systemic anti-VEGF therapy less than four weeks prior to enrollment or will be starting systemic anti-VEGF therapy while on the protocol.

-The participant has had intraocular surgery (including lens replacement surgery) within six weeks prior to enrollment.

-The participant has a history of (within the last six months), or current ocular or periocular infection (including any history of ocular herpes zoster or simplex).

-The participant has had a prior vitrectomy.

-The participant has a history of systemic or topical steroid use at any time during the 30 days prior to enrollment.

-The participant has participated in any other clinical study or is receiving, or has received any experimental treatment for AMD or any other investigational new drug within 12 weeks prior to the start of study treatment.

-The participant has medical problems that make consistent follow-up over the treatment period unlikely (e.g., stroke, severe MI, end stage malignancy), any contraindications to performing the necessary diagnostic studies (i.e., known allergy to indocyanine green or fluorescein dyes, etc.), or in general is a poor medical risk because of other systemic diseases or active uncontrolled infections.

-The participant has had insertion of a sclera buckle in the study eye.

-The participant has clinical evidence of scleral thinning (defined as an area of blue/grey discoloration of the sclera representing visualization of underlying choroidal tissue through a thinned area of sclera) seen at the time of external eye examination.

-The participant exhibits clinical signs of myopic retinopathy, or has a refraction of greater than spherical equivalent -8.00D in their current prescription. Pseudophakic participants may be enrolled in this study if there is no funduscopic evidence of degenerative myopia present and if there is no medical history prior to the participant's cataract surgery of either myopic retinopathy or a refraction of greater than spherical equivalent -8.00D.

-The participant has a history of a corneal transplant.

-The participant has known allergy to fluorescein or indocyanine green dyes.

-The participant has infectious conjunctivitis, keratitis, scleritis, or endophthalmitis.

-The participant is currently undergoing treatment for active systemic infection.

-The participant has a shellfish allergy, iodine allergy or liver disease.

Special Instructions:
Currently Not Provided
Keywords:
Lucentis
Indocyanine Green Angiography
Choroidal Neovascularization
Macular Degeneration
Ranibizumab
Recruitment Keyword(s):
Macualar Degeneration
Age-Related Macular Degeneration
AMD
Condition(s):
Macular Degeneration
Investigational Drug(s):
None
Investigational Device(s):
None
Intervention(s):
None
Supporting Site:
National Eye Institute

Contact(s):
Patient Recruitment and Public Liaison Office
Building 61
10 Cloister Court
Bethesda, Maryland 20892-4754
Toll Free: 1-800-411-1222
TTY: 301-594-9774 (local),1-866-411-1010 (toll free)
Fax: 301-480-9793

Electronic Mail:prpl@mail.cc.nih.gov

Citation(s):
Bressler NM, Bressler SB, Fine SL. Age-related macular degeneration. Surv Ophthalmol. 1988 May-Jun;32(6):375-413. Review.

[No authors listed] Laser photocoagulation of subfoveal neovascular lesions in age-related macular degeneration. Results of a randomized clinical trial. Macular Photocoagulation Study Group. Arch Ophthalmol. 1991 Sep;109(9):1220-31.

Pieramici DJ, Avery RL. Ranibizumab: treatment in patients with neovascular age-related macular degeneration. Expert Opin Biol Ther. 2006 Nov;6(11):1237-45. Review.

Active Accrual, Protocols Recruiting New Patients

If you have:


Command Menu Bar

Search The Studies | Help | Questions |
Clinical Center Home | NIH Home


Clinical Center LogoNational Institutes of Health Clinical Center Bethesda, Maryland 20892. Last update: 01/30/2009
Search The Studies Help Questions